Atreca is a biotechnology company developing novel therapeutics drawn from human immune responses, including effective anti-Âcancer immune responses. We are able to measure and analyze the structure of clinically relevant immune responses to identify the antibodies, T cell receptors, and targets that are key to successful treatment outcomes. Atrecaâs proprietary Immune Repertoire CaptureÂŽ technology profiles a patientâs immune response at the single-Âcell level at very high throughput essentially without bias or error, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen. The Company is advancing a pipeline of candidates designed to engage the human immune response in oncology and other indications, thus driving better therapeutic outcomes. Source
No articles found.
Aduro is dedicated to its mission to discover, develop, and commercialize immunoth...
Aduro is dedicated to its mission to discover, ...
Voom has developed a multi-platform wellness program to address both the injuries ...
Voom has developed a multi-platform wellness pr...
Admedus Limited is a bio medical group. The Group commercializes tissue engineerin...
Admedus Limited is a bio medical group. The Gro...
Seattle-based Atossa Genetics (NASDAQ: ATOS) is a clinical-stage biopharmaceutical...
Seattle-based Atossa Genetics (NASDAQ: ATOS) is...
SELLAS Life Sciences Group, Inc. is a late-stage biopharmaceutical company focused...
SELLAS Life Sciences Group, Inc. is a late-stag...
We're developing Vipax, the world's first portable, shelf-stable, broad-spectrum a...
We're developing Vipax, the world's first porta...
Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing ...
Trillium Therapeutics Inc. is a clinical stage ...
Join the National Investor Network and get the latest information with your interests in mind.